The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations

British Journal of Clinical Pharmacology

Volumn 75, Issue 6, 2013, Pages 1545-1547

  Elens, Laure ^a,b   Hesselink, Dennis A ^a   van Schaik, Ron H N ^a   van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ALGORITHM; ALLELE; GENOTYPE; HUMAN; KIDNEY TRANSPLANTATION; LETTER; PHARMACOGENETICS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; DOSE RESPONSE; GENETICS; HALF LIFE TIME;

ALGORITHMS; ALLELES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; TACROLIMUS;

EID: 84871407085     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12038     Document Type: Letter

References (6)

1. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-1583.
2. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12: 1383-1396.
3. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72: 948-957.
4. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tonshoff B, Keown P, Campbell S, Mamelok RD. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043-1051.
5. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125-130.
6. Passey C, Birnbaum AK, Brundage RC, Schladt DP, Oetting WS, Leduc RE, Israni AK, Guan W, Matas AJ, Jacobson PA. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics 2012; 13: 1141-1147.